EISAI Reaches Settlement of the Patent Infringement Relating to Eitest PIVKA II and Picolumi PIVKA-II
Eisai Co., Ltd.
EISAI Reaches Settlement of the Patent Infringement Relating to
Tokyo (April 4, 2000) - Eisai Co., Ltd. of Tokyo (President and CEO: Haruo Naito) today announced that a settlement has been reached with DaIIchi Radioisotope Laboratories, Ltd. of Tokyo (President: Junzo Okuda) concerning the patent infringement relating to the products Eitest PIVKA II and Picolumi PIVKA-II.
In a temporary injunction of March 31, 1999, the Tokyo District Court ordered the sales and production suspension of the DaIIchi Radioisotope Laboratories product PIVKA-II IRMA DaIIchi. DaIIchi Radioisotope Laboratories Ltd. honored the District Court's temporary injunction ceasing production and sales of the product and a subsequent settlement was reached.
Eitest PIVKA-II and Picolumi PIVKA-II are products used for the detection of liver cell cancer and were researched and developed by Eisai Co., Ltd. and the patent for this technology expires in March 2011. Eisai has licensed the production and sales of both products to its subsidiary, Sanko Junyaku of Tokyo (President: Ryo Watanabe).
For additional inquiries contact: